semaglutide news october 16 2025 Cardiovascular outcomes of and tirzepatide for patients with type 2 diabetes in clinical practice Most quit breakthrough weight-loss drug
Description
Non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH): Because of its role in lipid metabolism and energy storage, GIP modulation is explored for liver fat accumulation and metabolic liver disease
After six months, those who got a weekly semaglutide injection reported just 5 heavy drinking days per month, compared with 9 heavy drinking days for those in the placebo group
Earlier wearing off
[DOI] [PubMed] [Google Scholar] 34
West DB, Fey D, Woods SC
Mice in S-Low and S-High group were intraperitoneally injected with corresponding dose of semaglutide every week for 4 weeks
